Get the Stockscreener App
0.7717
0.31%
-0.0023
After Hours:
.77
-0.0017
-0.22%
Caribou Biosciences Inc stock is traded at $0.7717, with a volume of 3.82M.
It is down -0.31% in the last 24 hours and down -17.84% over the past month.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
See More
Previous Close:
$0.774
Open:
$0.77
24h Volume:
3.82M
Relative Volume:
3.33
Market Cap:
$73.97M
Revenue:
$34.48M
Net Income/Loss:
$-102.07M
P/E Ratio:
-0.5286
EPS:
-1.46
Net Cash Flow:
$-104.90M
1W Performance:
-2.98%
1M Performance:
-17.84%
6M Performance:
-58.96%
1Y Performance:
-79.20%
1-Day Range:
$0.7301
$0.7982
1-Week Range:
$0.7301
$0.899
52-Week Range:
$0.66
$3.93
Caribou Biosciences Inc Stock (CRBU) Company Profile
Name
Caribou Biosciences Inc
Sector
Industry
Phone
510-982-6030
Address
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
0.7717 | 73.97M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-08-23 | Initiated | Cantor Fitzgerald | Neutral |
| Oct-31-23 | Initiated | Evercore ISI | Outperform |
| Jul-11-23 | Initiated | Truist | Buy |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Nov-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-17-21 | Initiated | BofA Securities | Buy |
| Aug-17-21 | Initiated | Citigroup | Neutral |
| Aug-17-21 | Initiated | SVB Leerink | Outperform |
View All
Caribou Biosciences Inc Stock (CRBU) Latest News
Quarterly Snapshot: Quick and Current Ratios for Caribou Biosciences Inc (CRBU) - DWinneX
Caribou Biosciences Inc (CRBU) Stock: A Year of Decreases and Increases - investchronicle.com
Caribou Biosciences Inc (CRBU) receives an In-line rating from Evercore ISI - knoxdaily.com
Russell Investments Group Ltd. Boosts Holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Caribou Biosciences (CRBU) Restructures, Focuses on Key Oncology Programs - GuruFocus
Caribou stock in focus after portfolio shakeup (CRBU:NASDAQ) - Seeking Alpha
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs - marketscreener.com
Caribou Biosciences (CRBU) Shifts Focus to Oncology, Reduces Wor - GuruFocus
Caribou Biosciences Inc [CRBU] Shares Fall Approximately -78.12% Over the Year - knoxdaily.com
Caribou Biosciences extends cash runway, focuses on oncology - Investing.com
Caribou Biosciences, Inc. Announces Strategic Pipeline Prioritization and Workforce Reductions to Extend Cash Runway into H2 2027 - Nasdaq
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 ... - Enidnews.com
East Bay biotech to cut a third of its workforce, reset around two cancer programs - The Business Journals
Caribou Biosciences Inc (CRBU) stock analysis: A simple moving average approach - uspostnews.com
CRBU’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Recent Insider Activity Suggests Potential Gains for Caribou Biosciences Inc (CRBU) - knoxdaily.com
Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Bought by JPMorgan Chase & Co. - Defense World
Caribou Biosciences, Inc. (NASDAQ:CRBU) Stake Boosted by JPMorgan Chase & Co. - American Banking and Market News
Brokerages Set Caribou Biosciences, Inc. (NASDAQ:CRBU) PT at $10.33 - Defense World
Q1 Earnings Estimate for CRBU Issued By Leerink Partnrs - Defense World
THE ROSEN LAW FIRM, P. A., Caribou Biosciences, Inc. - The Bradford Era
Investigation announced for Long-Term Investors in shares - openPR.com
American Century Companies Inc. Grows Stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Sei Investments Co. Buys New Position in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Prudential Financial Inc. Sells 111,100 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Connect - markets.businessinsider.com
Caribou Biosciences Inc [CRBU] President and CEO makes an insider purchase of 20,000 shares worth 20400.0. - knoxdaily.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Reach Out - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Shareholders to Learn More About the Investigation - markets.businessinsider.com
Thrivent Financial for Lutherans Acquires 79,636 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Caribou Biosciences stock hits 52-week low at $0.71 - Investing.com India
Caribou Biosciences stock hits 52-week low at $0.71 By Investing.com - Investing.com South Africa
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Investors to Connect - markets.businessinsider.com
Bank of New York Mellon Corp Has $358,000 Stock Position in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com
Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives $10.33 Consensus Target Price from Analysts - Defense World
Caribou Biosciences stock hits 52-week low at $0.95 By Investing.com - Investing.com Canada
Caribou Biosciences stock hits 52-week low at $0.95 - Investing.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Investors to Learn More About the Investigation - Markets Insider
Caribou Biosciences’ (CRBU) “Buy” Rating Reiterated at HC Wainwright - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Reach Out - Markets Insider
Caribou Biosciences’ SWOT analysis: CRISPR pioneer’s stock faces critical juncture - Investing.com Canada
Truist Removes Price Target on Caribou Biosciences, Keeps Buy Rating; Price Target Was $19 - Marketscreener.com
US Bancorp DE Buys 26,467 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Connect - Markets Insider
Caribou Biosciences CEO Rachel E. Haurwitz buys $20,400 in stock By Investing.com - Investing.com Australia
Caribou Biosciences CEO Rachel E. Haurwitz buys $20,400 in stock - Investing.com India
Caribou Biosciences Inc Stock (CRBU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):